CHORDC1

Across TCGA pan-cancer cohorts, CHORDC1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CHORDC1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CHORDC1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CHORDC1 is over-expressed in tumor.

HNSC, LSCC, and LUAD are the cancer types where CHORDC1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHORDC1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.513	<.001	11	view →
LSCC	Male	II,III,IV	+0.777	<.001	9	view →
LUAD	Male	III,IV	+0.633	<.001	9	view →
PDAC	Female	II,III,IV	+0.481	<.001	8	view →
COAD	Female	II,III,IV	+0.215	<.001	8	view →
CCRCC	All	III,IV	+0.162	.001	7	view →
OV	All	All	+0.427	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CHORDC1–HNSC

Open the HNSC breakdown →